In brief: Chemeq, Acuron, Compumedics, Synchrotron
Tuesday, 19 July, 2005
Chemeq (ASX:CMQ) is in a trading halt in the lead-up to an announcement concerning the underwriting of AUD$20 million convertible bonds to Mizuho International, Stark Trading and Shephard Investments International, to which it committed itself in April.
Acuron's (ASX:AVP) wholly owned subsidiary Protex Healthcare (UK) will bring its sales and marketing activities in house by appointing medical and wound care sales representatives over the next few months. Meanwhile, Acuron appointed Fiona Taylor as company secretary, replacing Stephen Belben who will remain as finance director.
Compumedics (ASX:CMP) has reinforced its commitment to Asian sales growth with the appointment of Tim Gresham as Business Director, Asia and South American and Ben So as Senior Business Manager Asia.
The Australian Synchrotron and China's Beijing Synchrotron Radiation Facility have signed a collaboration partnership agreement allowing scientists to move freely between the two facilities. The Beijing Synchrotron Radiation Facility is part of the Institute of High Energy Physics within the Chinese Academy of Science.
Cartherics and Catalent announce enhanced partnership
To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...
Alliance seeks to boost regional capacity in clinical trials
Launched this week, the Barwon Health–Deakin University Clinical Trials Alliance is...
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
